A report on China’s new cell and gene therapy (CGT) rules says the regulatory update could change how developers structure trials, manufacturing, and commercial planning for CGT products in the world’s second-largest market for many advanced therapy categories. The update is positioned as a shift that may affect timelines and compliance expectations for future submissions. For companies with China-facing strategies, the rule change adds an additional layer of regulatory planning beyond clinical execution, particularly for developers balancing global development timelines and local evidence requirements. The emergence of new compliance expectations also increases the need for early alignment between sponsors and regulators on data packages and study designs.